ELI LILLY AND COMPANY Amortization of Intangible Assets
ELI LILLY AND COMPANY (LLY) reported Amortization of Intangible Assets of $488.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-02-12
- ELI LILLY AND COMPANY amortization of intangible assets for the quarter ending 2015-12-31 was $170.10M, a 25.07% increase year-over-year.
- ELI LILLY AND COMPANY amortization of intangible assets for the quarter ending 2015-09-30 was $154.10M, a 15.00% increase year-over-year.
- ELI LILLY AND COMPANY amortization of intangible assets for the quarter ending 2015-06-30 was $153.40M, a 14.39% increase year-over-year.
- ELI LILLY AND COMPANY amortization of intangible assets for the quarter ending 2015-03-31 was $154.20M, a 16.91% increase year-over-year.
- ELI LILLY AND COMPANY amortization of intangible assets for fiscal 2025 was $488.00M, a 11.75% decline from fiscal 2024.
- ELI LILLY AND COMPANY amortization of intangible assets for fiscal 2024 was $553.00M, a 9.29% increase from fiscal 2023.
- ELI LILLY AND COMPANY amortization of intangible assets for fiscal 2023 was $506.00M, a 12.71% decline from fiscal 2022.
- ELI LILLY AND COMPANY amortization of intangible assets for fiscal 2022 was $579.70M, a 7.81% decline from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $488.00M 10-K · filed 2026-02-12 | ||||
| 2024-12-31 | $553.00M 10-K · filed 2026-02-12 | $552.90M 10-K · filed 2025-02-19 | |||
| 2023-12-31 | $506.00M 10-K · filed 2026-02-12 | $505.60M 10-K · filed 2024-02-21 | |||
| 2022-12-31 | $579.70M 10-K · filed 2025-02-19 | ||||
| 2021-12-31 | $628.80M 10-K · filed 2024-02-21 | ||||
| 2020-12-31 | $428.20M 10-K · filed 2023-02-22 | ||||
| 2019-12-31 | $225.80M 10-K · filed 2022-02-23 | ||||
| 2018-12-31 | $361.30M 10-K · filed 2021-02-17 | $558.70M 10-K · filed 2019-02-19 | |||
| 2017-12-31 | $462.20M 10-K · filed 2020-02-19 | $683.40M 10-K · filed 2018-02-20 | |||
| 2016-12-31 | $517.20M 8-K · filed 2019-10-24 | $687.90M 10-K · filed 2017-02-21 | |||
| 2015-12-31 | $170.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $324.20M derived: sum of 2 quarters · filed 2018-02-20 | $477.60M derived: sum of 3 quarters · filed 2018-02-20 | $631.80M 10-K · filed 2018-02-20 | |
| 2015-09-30 | $154.10M 10-Q · filed 2015-10-30 | $307.50M derived: sum of 2 quarters · filed 2015-10-30 | $461.70M 10-Q · filed 2015-10-30 | $597.70M derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-06-30 | $153.40M 10-Q · filed 2015-07-30 | $307.70M 10-Q · filed 2015-07-30 | $443.60M derived: sum of 3 quarters · filed 2017-02-21 | $577.60M derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-03-31 | $154.20M 10-Q · filed 2015-04-30 | $290.20M derived: sum of 2 quarters · filed 2017-02-21 | $424.20M derived: sum of 3 quarters · filed 2017-02-21 | $558.30M derived: sum of 4 quarters · filed 2017-02-21 | |
| 2014-12-31 | $136.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $270.00M derived: sum of 2 quarters · filed 2017-02-21 | $404.10M derived: sum of 3 quarters · filed 2017-02-21 | $535.90M 10-K · filed 2017-02-21 | |
| 2014-09-30 | $134.00M 10-Q · filed 2015-10-30 | $268.10M derived: sum of 2 quarters · filed 2015-10-30 | $399.90M 10-Q · filed 2015-10-30 | $531.50M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-06-30 | $134.10M 10-Q · filed 2015-07-30 | $265.90M 10-Q · filed 2015-07-30 | $397.50M derived: sum of 3 quarters · filed 2016-02-19 | $529.70M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2014-03-31 | $131.90M 10-Q · filed 2015-04-30 | $263.40M derived: sum of 2 quarters · filed 2016-02-19 | $395.60M derived: sum of 3 quarters · filed 2016-02-19 | $540.80M derived: sum of 4 quarters · filed 2016-02-19 | |
| 2013-12-31 | $131.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $263.70M derived: sum of 2 quarters · filed 2016-02-19 | $408.90M derived: sum of 3 quarters · filed 2016-02-19 | $555.00M 10-K · filed 2016-02-19 | |
| 2013-09-30 | $132.20M 10-Q · filed 2014-10-29 | $277.40M derived: sum of 2 quarters · filed 2014-10-29 | $423.50M 10-Q · filed 2014-10-29 | $564.80M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-06-30 | $145.20M 10-Q · filed 2014-07-28 | $291.30M 10-Q · filed 2014-07-28 | $432.60M derived: sum of 3 quarters · filed 2015-02-19 | $573.40M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2013-03-31 | $146.10M 10-Q · filed 2014-04-28 | $287.40M derived: sum of 2 quarters · filed 2015-02-19 | $428.20M derived: sum of 3 quarters · filed 2015-02-19 | $561.30M derived: sum of 4 quarters · filed 2015-02-19 | |
| 2012-12-31 | $141.30M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $282.10M derived: sum of 2 quarters · filed 2015-02-19 | $415.20M derived: sum of 3 quarters · filed 2015-02-19 | $563.00M 10-K · filed 2015-02-19 | |
| 2012-09-30 | $140.80M 10-Q · filed 2013-10-30 | $273.90M derived: sum of 2 quarters · filed 2013-10-30 | $421.70M 10-Q · filed 2013-10-30 | ||
| 2012-06-30 | $133.10M 10-Q · filed 2013-07-26 | $280.80M 10-Q · filed 2013-07-26 | |||
| 2012-03-31 | $147.70M 10-Q · filed 2013-04-26 | ||||
| 2011-12-31 | $469.00M 10-K · filed 2014-02-19 | ||||
| 2010-12-31 | $385.70M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |